Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of GZR18 (Bofanglutide) in Liver Insufficiency
NCT07144098Phase 1Recruiting
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2025
- Primary completion
- Jul 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, open-label trial of bofanglutide in obesity and Overweight (4 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Maximum plasma concentration, Area under the plasma concentration-time curve from time zero to last observation and 1 more. Started Aug 2025; status: recruiting.
02
Drugs
bofanglutide
03
Conditions
obesityOverweight
Beyond the preview
Go deeper on NCT07144098.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07144098.